Jan 20, 2011
By:
Erik Greb
Last Friday, French daily Le Figaro reported that sanofi-aventis intended to reach an acquisition agreement with Genzyme that would value the latter company at roughly $76 per share, or a total of $20 billion.
|
Jan 19, 2011
By:
Erik Greb
Improvements in analytical techniques may call for a re-evaluation of the biopharmaceutical industry saying that "the process is the product."
|
Jan 13, 2011
By:
Erik Greb
Last week, the US Pharmacopeia published proposed standards for the content, language, format, and appearance of prescription drug labels in an effort to enhance patient understanding and safety.
|
Jan 6, 2011
By:
Erik Greb
US Senator Amy Klobuchar (D-MN) urged the US Food and Drug Administration and the pharmaceutical industry to address what she called an "unprecedented" shortage of prescription drugs, especially for chemotherapy.
|
New modular bioprocessing technology could quicken the response to an outbreak of disease.
Jan 2, 2011
By:
Erik Greb
New modular bioprocessing technology could quicken the response to an outbreak of disease.
|
Dec 23, 2010
By:
Erik Greb
A US Food and Drug Administration inspection completed on Dec. 9, 2010 revealed persistent deficiencies at McNeil Consumer Healthcare's Fort Washington, Pennsylvania, facility.
|
Dec 16, 2010
By:
Erik Greb
Abbott Laboratories (Abbott Park, IL), B. Braun Medical (Bethlehem, PA), and Roxane Laboratories, a subsidiary of Boehringer Ingelheim (Ingelheim am Rhein, Germany), agreed to pay the United States $421 million to settle False Claims Act allegations.
|
Dec 15, 2010
By:
Erik Greb
Equipment and Processing Report talked to Jonathan Seville, dean of the School of Engineering at the University of Warwick, to find out how positron-emission particle tracking could help pharmaceutical manufacturers gain process understanding.
|
Dec 6, 2010
By:
Erik Greb
Journalists continue to comb through the latest batch of diplomatic cables released by WikiLeaks, seeking to interpret the mass of raw information.
|
|
